Literature DB >> 8697619

Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type.

J Sobajima1, S Ozaki, T Okazaki, F Osakada, S Sumita, K Mori, K Nakao.   

Abstract

We analysed the clinical significance of ANCA in patients with ulcerative colitis. On either an indirect immunofluorescence assay or an ELISA with fixed neutrophils, 71% (25/35) of the patients were positive for ANCA. However, only half of them reacted with either cathepsin G or lactoferrin. Western blot assays revealed positive bands in 40% (10/25) of the antibody-positive patients. The sizes of the bands detected were approximately 58, 47, 44, 40, and 28 kD. No significant correlation was found between the ANCA positivity and various variables, i.e. disease activity, extent of lesion, or treatment of the disease. The anti-cathepsin G and 28-kD positivity, however, significantly correlated with a refractory type of ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697619      PMCID: PMC2200488          DOI: 10.1046/j.1365-2249.1996.d01-724.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  13 in total

1.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

2.  Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity.

Authors:  T Akamizu; S Ozaki; H Hiratani; H Uesugi; J Sobajima; Y Hataya; N Kanamoto; M Saijo; Y Hattori; K Moriyama; K Ohmori; K Nakao
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 3.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value.

Authors:  Evgenija Homsak; Dusanka Micetić-Turk; Borut Bozic
Journal:  Wien Klin Wochenschr       Date:  2010-05       Impact factor: 1.704

5.  The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis.

Authors:  Jin Ha Lee; Jae Hee Cheon; Eun Soo Kim; Moon Jae Chung; Wonseok Kang; Duk Hwan Kim; You Jung Ha; Jae Jun Park; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2009-06-09       Impact factor: 3.199

6.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

7.  Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC).

Authors:  J Sobajima; S Ozaki; H Uesugi; F Osakada; H Shirakawa; M Yoshida; K Nakao
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

8.  A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Authors:  Mao Zhang; Pariya Sukhumalchandra; Atim A Enyenihi; Lisa S St John; Sally A Hunsucker; Elizabeth A Mittendorf; Anna Sergeeva; Kathryn Ruisaard; Zein Al-Atrache; Patricia A Ropp; Haroon Jakher; Tania Rodriguez-Cruz; Gregory Lizee; Karen Clise-Dwyer; Sijie Lu; Jeffrey J Molldrem; Gary L Glish; Paul M Armistead; Gheath Alatrash
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

9.  Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD).

Authors:  C Roozendaal; M H Zhao; G Horst; C M Lockwood; J H Kleibeuker; P C Limburg; G F Nelis; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

10.  Defensins- and cathepsin G-ANCA in systemic lupus erythematosus.

Authors:  Hiroyuki Tamiya; Kenji Tani; Jyunya Miyata; Keiko Sato; Tomoyuki Urata; Battur Lkhagvaa; Shinsaku Otsuka; Shizuka Shigekiyo; Saburo Sone
Journal:  Rheumatol Int       Date:  2006-08-10       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.